Search

Learn about the different types of benign breast lumps.

… Friday, May 24, 2024 What should you do if you notice a lump in your breast? Don’t panic. See your doctor. “Many lumps turn out to be benign,” says Memorial Sloan Kettering Cancer Center breast radiologist Kimberly N. Feigin, MD , Acting Chief of Breast Radiology at MSK. “But the most important thing

New data from a study led by Memorial Sloan Kettering physicians that used targeted therapy for patients with the most common type of lung cancer has helped transform treatment for the disease.

… Tuesday, May 20, 2014 Data Supports Routine Tumor Genotyping for Patients with Advanced Lung Cancers; May Improve Survival New data from a study led by Memorial Sloan Kettering physicians that used targeted therapy for patients with the most common type of lung cancer has helped transform treatment for

Immunotherapy pioneers Michel Sadelain, MD, PhD, of Memorial Sloan Kettering Cancer Center (MSK), and Carl June, MD, of the University of Pennsylvania, have published a seminal review of the current landscape of chimeric antigen receptor (CAR) therapy in the New England Journal of Medicine (NEJM). In the comprehensive review article, Drs. Sadelain and June highlight the emerging immunotherapy treatment for hematologic cancers known as CAR T cells, which was developed at MSK. The paper is the first in a series being published by NEJM. Known as Frontiers in Medicine, it will showcase ways that new technologies are influencing contemporary medicine and science.

… Wednesday, July 4, 2018 Immunotherapy pioneers Michel Sadelain, MD, PhD, of Memorial Sloan Kettering Cancer Center (MSK), and Carl June, MD, of the University of Pennsylvania, have published a seminal review of the current landscape of chimeric antigen receptor (CAR) therapy in the New England Journal

A new drug is showing very encouraging results against pancreatic cancer, thanks to clinical trials of daraxonrasib at MSK and other hospitals.

… Thursday, May 7, 2026 A drug that may offer new hope for people facing pancreatic cancer has been authorized by the U.S. Food & Drug Administration (FDA) for expanded access, meaning more patients can take the drug while it is being studied.  Pancreatic cancer is one of the most aggressive types of cancer

… Tuesday, May 5, 2026 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Christopher D. Lima Elected 2025 AAAS Fellow   Christopher D. Lima Christopher D. Lima, PhD, Chair of the Structural Biology Program at the Sloan Kettering Institute and a Howard Hughes

Read how prostate cancer screening saved a man's life and inspired his activism for cancer awareness in the Black community.

… Friday, May 8, 2026   It started with a simple blood test. Eddie Baynes, a finance executive at Verizon and a proud Morehouse College graduate, joined a prostate cancer awareness drive with his fraternity brothers of Alpha Phi Alpha Fraternity, Inc. One of them, Derrick Butts, had survived the disease

Fifteen young scientists are poised to receive their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. Their years of dedication and training will be recognized on May 13, 2026, as part of Memorial Sloan Kettering’s 47th annual academic convocation.

… Monday, May 11, 2026   On May 13, 2026, 15 new PhD scientists will officially receive their degrees from the  Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) . The graduates will receive their diplomas as part of the 47th annual academic convocation and commencement ceremony held

A team of researchers from MSK has developed a new type of CAR T cell therapy that shows promise against acute myeloid leukemia (AML) in preclinical models.

… Tuesday, May 12, 2026 Developing effective immunotherapies for acute myeloid leukemia (AML) has long been hampered by a critical challenge: Therapy directed at killing the leukemia cells may also harm the body’s ability to make new, healthy blood cells. This happens because most of the proteins that

After a cancer diagnosis, one of the first and toughest decisions people face is how much to share in the workplace. Read more about working with cancer — and how MSK offers guidance and support.

… Monday, May 11, 2026 Any working person with cancer is forced to weigh the risks and benefits of sharing deeply personal news in the workplace, often before you can know what the diagnosis will mean. For those in leadership positions, that decision can be further complicated by a sense of responsibility

MSK doctors and scientists are leading the charge to find new and innovative ways to treat metastatic brain cancer.

… Tuesday, May 12, 2026   For patients who have been diagnosed with cancer that has spread to the brain from other parts of the body, there are more and more reasons to be hopeful. These types of tumors are increasingly being met with powerful, targeted treatments designed to eliminate them entirely, with